St. Baldrick's Foundation Announces 2026 Ambassadors
Los Angeles, California--(Newsfile Corp. - January 6, 2026) - The St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants in the U.S., is proud to announce its 2026 Ambassadors. Along with their families, these ambassadors will share their personal journeys and experiences with childhood cancer to raise awareness and inspire action to
2026-01-06 12:00 PM EST | St. Baldrick's Foundation
BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD") for the treatment of neurological disorders, today announced that it will be participating in the YAFO Capital Access Asia 2025 Partnering Forum, held in San Franc
2026-01-06 8:00 AM EST | BetterLife Pharma Inc.
Aleen Inc. Announces Upcoming Enhancements to the Personal Account
Toronto, Ontario--(Newsfile Corp. - January 6, 2026) - Aleen Inc. (CSE: ALEN.U), a digital wellness company, announces that starting in early 2026, it will begin rolling out new features and improvements within the Personal Account, its user-facing tool for managing wellness information. Planned enhancements include improved data organization, interactive visualizations, and a refined user experience, helping users gain clearer insights into personal wellness patterns wit
2026-01-06 8:00 AM EST | Aleen Inc.
Beckett's Kicks Off Multi-Channel Dry January Campaign Across Retail, Subscription Services, and Influencer Partnerships
Ontario and Los Angeles, California--(Newsfile Corp. - January 6, 2026) - Beckett's Inc. (CSE: BKTS) (OTCQB: BKTSF), a fast-growing non-alcoholic beverage brand has launched a national Dry January initiative spanning major retail, subscription, and influencer channels. The month-long campaign includes featured promotions at Total Wine & More, Walmart.com, Amazon.com, national non-alcoholic subscription service Raising the Bar, Los Angeles bottle shop Burden of Proof, along w
Food / Beverages, Cannabis, Health
2026-01-06 7:30 AM EST | Becketts Inc.
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Burlington, Ontario--(Newsfile Corp. - January 5, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that pursuant to the terms of its amended and restated secured convertible notes dated December 1, 2025 (the "Notes"), the Company intends to issue common shares ("Common Shares") in satisfaction of the accrued interest payable on December 31, 2025. The Company expects to issue the Common Shares no later than Januar
2026-01-05 5:30 PM EST | Rapid Dose Therapeutics Corp.
Adia Nutrition Inc. Announces Landmark Autism Spectrum Disorder Clinical Study Now Live on ClinicalTrials.gov
Winter Park, Florida--(Newsfile Corp. - January 5, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine through its subsidiary Adia Med, today announced that its patent-pending clinical study targeting Autism Spectrum Disorder (ASD) has gone live on ClinicalTrials.gov, marking a significant advancement in the company's research pipeline.
Healthcare and Hospitals, Health
2026-01-05 10:21 AM EST | Adia Nutrition Inc.
RELIEF AI's Digital Well-Being Innovation "RELIEF AI - Naia" Recognized as a "Recommended Measure for 2025" by Leading German Health Promotion Organization
Toronto, Ontario--(Newsfile Corp. - January 5, 2026) - Relief AI Inc. (the "Company "or "Relief AI") is proud to announce that its groundbreaking digital well-being solution, RELIEF AI - Naia, has been officially recognized as a "Recommended Measure 2025" by the Gesellschaft für Prävention (GpeV), a leading German health promotion organization. This official recognition was granted after a thorough review and evaluation by the GPeV, which cited the exceptional value of
Technology, Healthcare and Hospitals, Health
2026-01-05 7:00 AM EST | Relief AI Inc.
CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition
Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process. On December 18, 2025, a Presidential Exe
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-01-05 7:00 AM EST | Cannabis Bioscience International Holdings
TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026
Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year ahead in 2026. As 2025 ends, the Company reflects on a transformative year marked by significant commercial progress, strategi
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-02 5:00 PM EST | TempraMed Technologies Ltd
FendX Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, announces that it has extended the term of a consulting agreement, as amended, previously announced June 11, 2025 and November 21, 2025, with a third party branding expert to provide strate
Technology, Healthcare and Hospitals, Health
2025-12-31 6:00 PM EST | FendX Technologies Inc.
TempraMed Deepens Asian Market Penetration with Expanded Distribution Partnership and Meaningful Commercial Order in South Korea
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce today a new commercial order and an extension of its distribution partnership in South Korea. The expanded collaboration with Mavericks Co. Ltd ("Mavens"), a South Korea–
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-31 5:00 PM EST | TempraMed Technologies Ltd
Izotropic Announces AGM Results
British Columbia and Sacramento, California--(Newsfile Corp. - December 31, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the results of its Annual General and Special Meeting held on December 29, 2025. Company mat
2025-12-31 4:31 PM EST | Izotropic Corporation
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Calgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (the "Company" or "Hemostemix"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, and vascular dementia, is pleased to announce that it has closed a non-brokered private placement for aggregate gross proceed
Biotechnology, Pharmaceuticals, Health
2025-12-31 2:38 PM EST | Hemostemix Inc.
Cheelcare Announces Second Quarter Fiscal 2026 Financial Results
Markham, Ontario--(Newsfile Corp. - December 30, 2025) - Cheelcare Inc. (TSXV: CHER) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, today announced its financial results for the second quarter ended October 31, 2025. All figures are in Canadian dollars unless otherwise noted. Operational Highlights (Three Months Ended October 31, 2025) Manufacturing transition completed: Successfully completed the transition of inventory, equipme
2025-12-30 4:30 PM EST | Cheelcare Inc.
Aleen Inc. - 2025: A Year of Insight, Clarity, and Growth
Toronto, Ontario--(Newsfile Corp. - December 30, 2025) - Aleen Inc. (CSE: ALEN-U), a digital wellness company, reflects on 2025 as a year marked by meaningful growth, product development, and strategic progress in the digital wellness space - all delivered within a safe, transparent, and non-medical framework. In 2025, Aleen Inc. reached an important corporate milestone with its listing on the Canadian Securities Exchange (CSE) on June 6, 2025, trading under the ticker ALEN.U. Th
2025-12-30 8:00 AM EST | Aleen Inc.
Adia Nutrition Inc. Recaps Transformative 2025: Explosive Growth, Strategic Focus, and Path to Nasdaq Uplisting
Winter Park, Florida--(Newsfile Corp. - December 29, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions, today announced a year-end recap of its pivotal 2025 achievements. The company delivered remarkable financial performance, operational expansion, and strategic milestones, positioning itself for sustained growth and an anticipated Nasdaq uplisting. "2025 has been a defining year of execution and momentum f
Healthcare and Hospitals, Health
2025-12-29 9:00 AM EST | Adia Nutrition Inc.
CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways
Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that it is pursuing a new patent for an investigational therapy designed to address opioid addiction, a condition that continues to claim tens of thousands of lives each year in the United States. According to U.S. public health data, more than 700,000 people have died
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-12-29 7:00 AM EST | Cannabis Bioscience International Holdings
TempraMed Launches New Product, VIVI Cap Smart, Expanding Its Portfolio to Include a Digital Health Offering
Highlights: Expands TempraMed's product portfolio and adds a digital component to track and record medication use. First in the world platform that turns almost every insulin and GLP-1 pens to be connected and with a temperature shield. Unlocks significant pharma, healthcare provider, and real-time data opportunity to track compliance, efficacy, side effects, and other important information. Adds subscription-based business model to produ
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-26 5:00 PM EST | TempraMed Technologies Ltd
Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage
Centennial, Colorado--(Newsfile Corp. - December 24, 2025) - The Obesity Medicine Association (OMA) released its Position Statement on Medicare and Medicaid Coverage and Expanded Access to Obesity Medications, detailing the association's recommendations and support for emerging federal policies expected to dramatically improve treatment access for millions of Americans living with obesity. The OMA commends the Centers for Medicare
Healthcare and Hospitals, Health
2025-12-24 8:00 AM EST | Obesity Medicine Association
A Year of Purpose and Progress: Dr. Christina Rahm Celebrates Global Growth, Scientific Breakthroughs, and International Honors
Franklin, Tennessee--(Newsfile Corp. - December 23, 2025) - From global stages and scientific breakthroughs to philanthropic leadership and international recognition, 2025 has marked a defining year for Dr. Christina Rahm. As Chief Science Officer of The ROOT Brands and founder of DRC Ventures, Dr. Rahm continues to lead at the intersection of science, sustainability and purpose-driven innovation. Her work this year has expanded far beyond the laboratory, spanning continents, empowering commu
Biotechnology, Food / Beverages, Health
2025-12-23 11:41 AM EST | DRC Ventures